FUNDING & OPPORTUNITIES 

Are you a start-up interested in bio-incubator space?

Become part of our vibrant Institute in a much sought after location on Cambridge Biomedical Campus. The Milner Therapeutics Institute has limited space for research intensive, R&D companies, working in an areas related to the Institute’s expertise (e.g. functional genomics, early target discovery, therapeutics). You will be working side by side with academics, entrepreneurs and industry scientists.

To discuss, please contact contact@milner.cam.ac.uk

Bio-spark is an education and research programme that provides support for such early-stage scientists, including but not limited to those engaged in a PhD or Postdoc. Bio-spark provides mentorship by inspirational individuals, gives opportunity to sample different company environments, and provides mentorship that may lead to the formation of companies. This programme gives a unique set of young scientists tools to progress in business and entrepreneurship.

Bio-spark fellows will be chosen in recognition of their entrepreneurial potential. They will be exceptional individuals who think beyond the normal boundaries, have an appetite for innovation, and are in search of the intellectual spark that will make a difference to human health.

To learn more, visit their Bio-spark webpage.

We are delighted to have joined a three-year collaboration with the science funding agency ARIA and multiple Cambridge partners, to engineer a new generation of neuro-technologies designed to treat depression, dementia, chronic pain, epilepsy and injuries to the nervous system.

Cambridge NeuroWorks will support the development of breakthrough technologies, from electronic brain implants to brain-computer interfaces, designed to improve lives globally. It will include two programmes: one to bring together innovators from around the UK with exciting ideas in neuro-technology, and provide funding to rapidly test their ideas in Cambridge, along with mentorship; and a second for those across the UK who have proof of concept validation for their neuro-technology and need support to turn it into a business. For both these programmes, the Milner Therapeutics Institute will provide access to lab space and mentoring support, and will bring together academic, clinical and industry partners across technology and therapeutics both in-person and online via Connect: Health Tech.

To learn more, visit Cambridge NeuroWorks.

C:HT catalyses connections which spark collaboration at the interface between medicine and technology, tapping into Cambridge’s unique ecosystem to enable partnerships, innovation and future growth.

By strengthening interdisciplinary bridges between academia, industry and healthcare C:HT facilitates real-world possibilities transforming innovative ideas into tangible outcomes that benefit society.

https://connect.cam.ac.uk

Our pharma partners in the Milner Therapeutics Consortium are working together with academics at the University, Babraham and Wellcome Sanger Institutes to better understand disease mechanisms and to discover and validate new therapeutic targets. These pre-clinical projects range from reagent sharing and 6-month pilots to 2-year postdoctoral funded collaborations and are expected to lead to joint publications with the company partners.

Call closing: 7 March 2025

Visit the Consortium Call page for more information.

The Founders Growth Community is a collaborative effort between the Milner Therapeutics Institute, Babraham Research Campus, o2h group, Illumina Ventures, and Start Codon. The initiative comprises a series of workshops, masterclasses, round tables, and panel discussions, tailored for founders/CEOs in the scale-up, commercialisation, or growth phase. The focus is on exploring what comes next for founders/CEOs in terms of education, learning, and community development.

Follow Founders Growth Community on LinkedIn: https://www.linkedin.com/company/founders-growth-community